No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer By Ogkologos - August 19, 2025 745 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ASTER 70s study Source RELATED ARTICLESMORE FROM AUTHOR Non-pharmacological interventions – are they important to patients with cancer? Two novel bispecific antibodies in combination with chemotherapy show efficacy in neuroendocrine carcinomas Sacituzumab tirumotecan plus pembrolizumab significantly prolongs progression-free survival in advanced non-small cell lung cancer MOST POPULAR Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Got the COVID Blues? August 12, 2020 Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... December 3, 2021 A Genome-Wide Association Study of irAEs Identifies New Genome-Wide Significant Associations... January 20, 2023 Load more HOT NEWS “World’s Tiniest Baby” Has Been Released From The Hospital A Daily Survival Kit for Serious Illness A Deep-Learning Model Predicts the Primary System Origin of Malignant Cells... One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories...
